ondansetron has been researched along with Cognitive Dysfunction in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials." | 9.27 | Ondansetron - a promising adjunctive treatment for persistent schizophrenia. ( Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Thomas, N, 2018) |
| "This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials." | 5.27 | Ondansetron - a promising adjunctive treatment for persistent schizophrenia. ( Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Thomas, N, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulkarni, J | 1 |
| Thomas, N | 1 |
| Hudaib, AR | 1 |
| Gavrilidis, E | 1 |
| Gurvich, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia[NCT01121042] | Phase 3 | 85 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ondansetron and Cognitive Dysfunction
| Article | Year |
|---|---|
Ondansetron - a promising adjunctive treatment for persistent schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognitive Dysfunction; Double-Blind Method; Drug Therapy, Combination; | 2018 |